Vanda Pharmaceuticals Management
Management criteria checks 2/4
Vanda Pharmaceuticals' CEO is Mihael Polymeropoulos, appointed in May 2003, has a tenure of 22.67 years. total yearly compensation is $3.90M, comprised of 23.9% salary and 76.1% bonuses, including company stock and options. directly owns 3.95% of the company’s shares, worth $18.99M. The average tenure of the management team and the board of directors is 6.9 years and 6.3 years respectively.
Key information
Mihael Polymeropoulos
Chief executive officer
US$3.9m
Total compensation
| CEO salary percentage | 23.95% |
| CEO tenure | 22.7yrs |
| CEO ownership | 4.0% |
| Management average tenure | 6.9yrs |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus
Jan 01
New Indications And Pipeline Advances Will Strengthen Position
Expansion of Fanapt's sales and marketing efforts is expected to drive significant revenue growth through increased brand awareness and prescriber engagement.Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids
Sep 05Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over
Aug 08Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest
Jun 18Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much
Apr 05Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Feb 15
Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash
Feb 13Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement
Feb 10News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts
Nov 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$84m |
| Jun 30 2025 | n/a | n/a | -US$67m |
| Mar 31 2025 | n/a | n/a | -US$44m |
| Dec 31 2024 | US$4m | US$933k | -US$19m |
| Sep 30 2024 | n/a | n/a | -US$16m |
| Jun 30 2024 | n/a | n/a | -US$11m |
| Mar 31 2024 | n/a | n/a | -US$5m |
| Dec 31 2023 | US$4m | US$897k | US$3m |
| Sep 30 2023 | n/a | n/a | US$12m |
| Jun 30 2023 | n/a | n/a | US$15m |
| Mar 31 2023 | n/a | n/a | US$16m |
| Dec 31 2022 | US$4m | US$815k | US$6m |
| Sep 30 2022 | n/a | n/a | US$6m |
| Jun 30 2022 | n/a | n/a | US$11m |
| Mar 31 2022 | n/a | n/a | US$18m |
| Dec 31 2021 | US$6m | US$769k | US$33m |
| Sep 30 2021 | n/a | n/a | US$34m |
| Jun 30 2021 | n/a | n/a | US$32m |
| Mar 31 2021 | n/a | n/a | US$32m |
| Dec 31 2020 | US$3m | US$746k | US$23m |
| Sep 30 2020 | n/a | n/a | US$19m |
| Jun 30 2020 | n/a | n/a | US$114m |
| Mar 31 2020 | n/a | n/a | US$117m |
| Dec 31 2019 | US$4m | US$721k | US$116m |
Compensation vs Market: Mihael's total compensation ($USD3.90M) is above average for companies of similar size in the US market ($USD2.28M).
Compensation vs Earnings: Mihael's compensation has increased whilst the company is unprofitable.
CEO
Mihael Polymeropoulos (65 yo)
Dr. Mihael H. Polymeropoulos, M.D., founded Vanda Pharmaceuticals, Inc. in 2003. He serves as Chairman of The Board at Vanda Pharmaceuticals Inc since June 2021 and has been its Chief Executive Officer, Pr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 22.7yrs | US$3.90m | 3.95% $ 19.0m | |
| Senior VP | 5.8yrs | US$1.45m | 0.15% $ 700.6k | |
| Senior VP | 7.4yrs | US$1.45m | 0.087% $ 419.6k | |
| Senior VP & Chief Marketing Officer | 6.4yrs | US$1.06m | 0.11% $ 530.2k | |
| Senior Vice President of Business Development | 8.8yrs | US$1.42m | 0.28% $ 1.4m | |
| Chief People Officer | 6.4yrs | no data | no data |
Experienced Management: VNDA's management team is seasoned and experienced (6.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 22.7yrs | US$3.90m | 3.95% $ 19.0m | |
| Lead Independent Director | 20.1yrs | US$336.86k | 0.20% $ 961.2k | |
| Independent Director | 2.8yrs | US$285.03k | 0.086% $ 415.0k | |
| Independent Director | 6.3yrs | US$306.86k | 0.10% $ 486.5k | |
| Independent Director | 5.9yrs | US$282.50k | 0.064% $ 307.8k | |
| Independent Director | 6.3yrs | US$302.91k | 0.11% $ 521.3k |
Experienced Board: VNDA's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/07 06:46 |
| End of Day Share Price | 2026/01/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vanda Pharmaceuticals Inc. is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Olivia Brayer | BofA Global Research |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |